Physician profile
Stephanie Devault
NPI 1265848535
$2,114.54
in general payments reported to CMS, 2019-2025
25 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $375 · 2022: $129 · 2023: $504 · 2024: $694 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,348 · Education: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,348.08 |
| Education | $262.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $408.12 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $334.70 | 2021-2025 | Fasenra, Breztri |
| Sanofi-Aventis U.S. LLC | $189.98 | 2023-2024 | |
| Genzyme Corporation | $180.03 | 2023-2024 | |
| Mylan Specialty L.P. | $136.48 | 2023-2024 | Yupelri |
| Abiomed | $123.34 | 2024 | Impella |
| Harmony Biosciences LLC | $109.31 | 2024-2025 | |
| Boston Scientific Corporation | $100.67 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.10 | 2022-2023 | Ofev |
| Axsome Therapeutics, INC. | $45.95 | 2023 | Sunosi |
| Neurocrine Biosciences, INC. | $45.93 | 2025 | |
| Amgen INC. | $44.36 | 2023-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $39.85 | 2025 | Dupixent |
| Baxter Healthcare | $38.09 | 2023-2024 | Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System |
| Pfizer INC. | $36.99 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $35.65 | 2022 | |
| Insmed, INC. | $35.04 | 2025 | Brinsupri, Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $28.22 | 2024 | Glassia |
| Sk Life Science, INC. | $25.78 | 2022 | |
| Viatris Specialty LLC | $23.32 | 2025 | Yupelri |
| United Therapeutics Corporation | $22.35 | 2022 | |
| Pulmonx Corporation | $17.90 | 2025 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Sunovion Pharmaceuticals INC. | $15.30 | 2021 | |
| Philips North America LLC | $15.05 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $15.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Devault listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.